摘要目的 探讨重症肌无力(MG)患者小剂量他克莫司治疗2年复发率及其影响因素.方法 回顾性分析2011年2月至2016年2月接受他克莫司治疗的110例MG患者的临床资料,均至少随访2年,分析影响MG患者复发的危险因素.结果 随访期间共49例患者复发,复发率为44.5％(49/110).Logistic回归分析结果显示,自行停减药、危象史和合并糖尿病是影响MG患者复发的独立危险因素(OR=134.113、8.850和6.652,P<0.01或<0.05).结论 MG患者小剂量他克莫司治疗2年期间复发率较高,应避免自行减停药,特别是既往有危象史的患者;糖尿病患者需要控制血糖稳定以避免复发.

abstractsObjective To identify the 2- year recurrence- related factors in patients with myasthenia gravis (MG) after treatment of low-dose tacrolimus. Methods The clinical data of 100 MG patients treated with low- dose tacrolimus from February 2011 to February 2016 were retrospectively analyzed. All patients were followed up at least 2 years, and the risk factors affecting the recurrence of MG patients were analyzed. Results At the end of follow-up, there were 49 cases who had recurrence, and the recurrence rate was 44.5％ (49 / 110). Logistic regression analysis result showed that reducing dosage or withdrawal, MG crisis and diabetes mellitus were the independent risk factors for recurrence of MG patients (OR = 134.113, 8.850 and 6.652; P < 0.01 or <0.05). Conclusions The rate of recurrence with low- dose tacrolimus treatment in patients with MG during 2 years is higher. Reducing dosage or withdrawal should be avoided, especially in patients with a history of MG crisis. Patients with diabetics mellitus need to control blood glucose stability to avoid recurrence.